



ASX Announcement 26 May 2020

NOT FOR DISTRIBUTION OR RELEASE IN THE UNITED STATES

ELIXINOL SUCCESSFULLY COMPLETES RETAIL ENTITLEMENT OFFER

Elixinol Global Limited (**Elixinol** or the **Company**) (**ASX:EXL; OTC:ELLXF**) is pleased to announce the successful completion of the retail component of its accelerated non-renounceable pro rata entitlement offer (**Retail Entitlement Offer**).

Completion of the Retail Entitlement Offer represents the second stage of Elixinol's \$11.0 million accelerated non-renounceable pro-rata entitlement offer (**Entitlement Offer**), details of which were announced to ASX on Tuesday, 5 May 2020. The institutional component of the Entitlement Offer closed 6 May 2020.

The Retail Entitlement Offer closed at 5.00pm (AEST) on Thursday, 21 May 2020 and raised approximately \$5.6 million (after including the proceeds of the partial underwriting up to approximately \$2.8 million).

The Retail Entitlement Offer provided eligible retail shareholders of Elixinol the opportunity to subscribe for 1 new fully paid ordinary share in Elixinol (**New Share**) for every 2.51 existing fully paid ordinary shares which they held in Elixinol as at 7.00pm (AEST) on Thursday, 7 May 2020 (**Entitlement**), at a price of \$0.20 per New Share. Eligible retail shareholders who took up their Entitlement in full under the Retail Entitlement Offer were invited to apply for additional New Shares (**Additional New Shares**), with any scale-back at the absolute discretion of Elixinol. Elixinol confirms that all shareholders who applied for Additional New Shares in excess of their Entitlement will have their applications allotted in full.

Elixinol received valid applications from eligible retail shareholders for approximately 15.6 million New Shares (including Additional New Shares) under the Retail Entitlement Offer equating to approximately \$3.1 million and implying a take-up rate by eligible retail shareholders of approximately 55.2%. The remaining approximately 12.7 million New Shares not taken up by eligible retail shareholders under the Retail Entitlement Offer, which equates to approximately \$2.5 million, will be allocated to sub-underwriters under the Retail Entitlement Offer.

Elixinol's CEO, Oliver Horn, commented: "*We are very pleased with the overall result of the capital raising. Our strategy of creating a global Elixinol branded CBD supplements business has clearly resonated with our existing shareholders and new investors. The roll out of our new Elixinol range is progressing well in the US and Europe and we are now looking forward*



to further implementing our branded consumer strategy whilst navigating the short-term COVID challenges.”

New Shares and Additional New Shares will be issued under the Retail Entitlement Offer on Tuesday, 2 June 2020 and are expected to commence trading on ASX on a normal settlement basis on Wednesday, 3 June 2020.

Holding statements are expected to be dispatched on Wednesday, 3 June 2020.

Bell Potter Securities Limited acted as the lead manager and underwriter to the Offer.

This document was authorised to be given to the ASX by the Board of the Company.

For more information please contact:

Ron Dufficy
Chief Financial Officer
ron.dufficy@elixinolglobal.com

About Elixinol Global

Elixinol Global Limited (ASX:EXL; OTC:ELLXF) is a global leader in the hemp derived CBD industry, innovating, manufacturing and selling hemp derived CBD products. The Company's simplified business model is focusing on:

- In the Americas, innovating, manufacturing and selling high quality Elixinol branded hemp derived CBD products based in Colorado, USA
- In Europe & UK, educating and selling high quality Elixinol branded and co-branded hemp derived CBD products based in Amsterdam, The Netherlands
- In Australia, providing stronger unified planning and support across the group to enable the various regional offices to focus on operational strategy and execution through its Global Executive Office based in Sydney, Australia
- Across the Rest of World, expanding distribution of Elixinol branded hemp derived CBD products through reputable distributors as key markets open.

See more at www.elixinolglobal.com

NOT FOR DISTRIBUTION OR RELEASE IN THE UNITED STATES

This announcement may not be distributed or released in the United States. This announcement does not constitute an offer to sell, or the solicitation of an offer to buy, any securities in the United States or any other jurisdiction in which such an offer would be illegal. The securities referred to in this Presentation have not been, and will not be, registered under the U.S. Securities Act of 1933, as amended (the U.S. Securities Act), or the securities laws of any state or other jurisdiction of the United States. Accordingly, the New Shares offered and sold under the Entitlement Offer may not be offered or sold, directly or indirectly, in the United States unless they have been registered under the U.S. Securities



Act (which the Company has no obligation to do) or are offered or sold pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the U.S. Securities Act and applicable securities laws of any state or other jurisdiction of the United States. Each person that reviews the information contained in this Presentation that is in the United States will be deemed to represent (a) that it is either (1) a “qualified institutional buyer” within the meaning of Rule 144A of the U.S. Securities Act or (2) a dealer or other professional fiduciary organised or incorporated in the United States that is acting for a discretionary or similar account (other than an estate or trust) held for the benefit or account of persons that are not “U.S. persons” (as defined in Rule 902(k) of the U.S. Securities Act) for which it has, and is exercising, investment discretion, within the meaning of Rule 902(k)(2)(i) of Regulation S, in reliance on Regulation S, and (b) and agree that it will not forward or deliver this Presentation, electronically or otherwise, to any other person.